The Mass-SIREN Group
Mass-SIRN 集团
基本信息
- 批准号:10197232
- 负责人:
- 金额:$ 16.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-07-15 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:Accident and Emergency departmentAcuteAdministrative CoordinationAreaBostonCardiologyCardiopulmonaryChildClinicalClinical ResearchClinical TrialsClinical Trials NetworkCollaborationsCommunity HospitalsDataDiseaseEmergency CareEmergency Department patientEmergency SituationEmergency researchEnrollmentEnsureFundingGeneral HospitalsHematologyHospitalsIndividualInfrastructureInternationalIsraelJointsLeadershipMassachusettsMedicalMedical centerMedical emergencyModelingNeurologicNeurologyNew EnglandOperative Surgical ProceduresPatient CarePatient RecruitmentsPatientsPediatric HospitalsPerformancePositioning AttributePre-hospital settingPre-hospitalization careProtocol ComplianceProtocols documentationProviderPublic HealthPublicationsPulmonologyRecording of previous eventsResearchResearch InfrastructureResearch PersonnelResourcesRuralSpecialistTrainingTraumaTrauma ResearchUniversitiesWomanacute careclinical centerdesignexperienceflexibilityimprovedinnovationmedical specialtiesmembernovelpragmatic trialprovider networksrural settingsuburbtertiary careunderserved minority
项目摘要
This application will create a Network Clinical Center (Hub) for the Strategies to Innovate EmeRgENcy
Care Clinical Trials Network (SIREN). We propose an integrated, collaborative team of high volume tertiary
care medical centers with expertise in emergency care clinical research. The team includes an administrative
Hub at Massachusetts General Hospital (MGH) with Spokes across the state including Baystate Medical
Center, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Boston Medical Center, Brigham &
Women's Hospital, UMass Memorial Medical Center, and St. Vincent Hospital. The Mass-SIREN Group will be
managed by a Steering Committee including leaders from each of the member hospitals. It will function
administratively as a Hub and Spoke model, but operationally as a collaborative team of medical centers. Our
team also includes nationally- and internationally-recognized leaders in neurology, cardiology, pulmonology,
hematology, and trauma; we will propose novel ideas for the SIREN network, and innovative solutions to
common problems in clinical trials including enrollment and retention. Specific Aims include:
Aim 1: To establish an administrative Hub for the SIREN Clinical Trials Network at MGH. This Hub will
enroll in each clinical trial. Additionally it will provide administrative coordination across the entire team.
Aim 2. To establish the Mass-SIREN Steering Committee, an integrated leadership team that will
coordinate trial management and enrollment across all of our centers.
Aim 3. To provide our existing network of prehospital providers with the regulatory and educational
infrastructure to ensure that trained EMS teams can successfully participate in SIREN clinical trials.
Aim 4. To further establish the Mass-SIREN Steering Committee as innovative leaders in emergency
care research. We will leverage our individual areas of expertise, our local co-investigators, and our colleagues
with subspecialty expertise to design and propose innovative trials for the entire SIREN network.
Our academic centers have experience conducting clinical emergency care research, and all have
existing pools of trained clinical research coordinators that actively screen in the Emergency Department (ED)
to manage enrollment and protocol compliance. Our hospitals see a wide range of patients, including children,
underserved minorities, as well as those in urban, suburban, and rural settings. We include all major
prehospital providers in Boston and across Massachusetts. Finally, this application highlights our long history
of demonstrated interdisciplinary relationships, and that our team has a proven record of joint collaboration,
trial performance, and scientific publication.
Overall, the MASS-Siren Group includes both the breadth and depth of experience and resources to be
an outstanding Network Clinical Center for SIREN.
该应用程序将为创新应急策略创建一个网络临床中心(中心)
护理临床试验网络 (SIREN)。我们建议建立一个由大量高等教育机构组成的综合协作团队
具有紧急护理临床研究专业知识的护理医疗中心。该团队包括行政人员
马萨诸塞州总医院 (MGH) 的中心,在全州范围内进行辐射,包括 Baystate Medical
中心、贝斯以色列女执事医疗中心、波士顿儿童医院、波士顿医疗中心、百翰医院
妇女医院、麻省大学纪念医疗中心和圣文森特医院。 Mass-SIRN 集团将
由各成员医院的领导组成的指导委员会管理。它将发挥作用
行政上采用中心辐射模型,但操作上采用医疗中心协作团队。我们的
团队还包括神经病学、心脏病学、肺病学、
血液学和创伤学;我们将为 SIREN 网络提出新颖的想法,并提出创新的解决方案
临床试验中的常见问题包括入组和保留。具体目标包括:
目标 1:在 MGH 建立 SIREN 临床试验网络的管理中心。该中心将
参加每个临床试验。此外,它将为整个团队提供行政协调。
目标 2. 建立 Mass-SIREN 指导委员会,这是一个综合领导团队,将
协调我们所有中心的试验管理和注册。
目标 3. 为我们现有的院前提供者网络提供监管和教育
确保训练有素的 EMS 团队能够成功参与 SIREN 临床试验的基础设施。
目标 4. 进一步建立 Mass-SIREN 指导委员会作为紧急情况下的创新领导者
护理研究。我们将利用我们各个领域的专业知识、当地的联合研究人员和同事
拥有专科专业知识,为整个 SIREN 网络设计和提出创新试验。
我们的学术中心拥有进行临床急救研究的经验,并且都拥有
现有的训练有素的临床研究协调员在急诊科 (ED) 中积极进行筛查
管理注册和协议合规性。我们的医院收治各种各样的患者,包括儿童、
服务不足的少数群体以及城市、郊区和农村地区的少数群体。我们包括所有主要
波士顿和马萨诸塞州各地的院前提供者。最后,这个应用程序凸显了我们悠久的历史
已证明的跨学科关系,并且我们的团队拥有良好的联合合作记录,
试验性能和科学发表。
总体而言,MASS-Siren 集团拥有广度和深度的经验和资源,
SIREN 的杰出网络临床中心。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joshua N Goldstein其他文献
Acute care bundles should be used for patients with intracerebral haemorrhage: An expert consensus statement
脑出血患者应使用急性护理集束:专家共识声明
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:6.1
- 作者:
A. Parry;Susann J. Järhult;N. Kreitzer;A. Morotti;Danilo S. Toni;D. Seiffge;A. D. Mendelow;Hiren Patel;H. Brouwers;C. Klijn;Thorsten Steiner;W.B. Gibler;Joshua N Goldstein - 通讯作者:
Joshua N Goldstein
Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage.
脑出血后抗凝逆转的时间和结果。
- DOI:
10.1001/jamaneurol.2024.0221 - 发表时间:
2024 - 期刊:
- 影响因子:29
- 作者:
Kevin N. Sheth;Nicole Solomon;Brooke Alhanti;Steven R. Messé;Ying Xian;Deepak Bhatt;J. C. Hemphill;Jennifer A Frontera;Ray Chang;Ilya M Danelich;Joanna Huang;Lee H. Schwamm;Eric E Smith;Joshua N Goldstein;Brian C. Mac Grory;Gregg C Fonarow;Jeffrey Saver - 通讯作者:
Jeffrey Saver
Joshua N Goldstein的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joshua N Goldstein', 18)}}的其他基金
Predictors of hematoma expansion in acute intracerebral hemorrhage
急性脑出血血肿扩张的预测因子
- 批准号:
8423067 - 财政年份:2009
- 资助金额:
$ 16.76万 - 项目类别:
Predictors of hematoma expansion in acute intracerebral hemorrhage
急性脑出血血肿扩张的预测因素
- 批准号:
7660841 - 财政年份:2009
- 资助金额:
$ 16.76万 - 项目类别:
Predictors of hematoma expansion in acute intracerebral hemorrhage
急性脑出血血肿扩张的预测因素
- 批准号:
7777262 - 财政年份:2009
- 资助金额:
$ 16.76万 - 项目类别:
Predictors of hematoma expansion in acute intracerebral hemorrhage
急性脑出血血肿扩张的预测因子
- 批准号:
8220960 - 财政年份:2009
- 资助金额:
$ 16.76万 - 项目类别:
相似国自然基金
Tenascin-X对急性肾损伤血管内皮细胞的保护作用及机制研究
- 批准号:82300764
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
活性脂质Arlm-1介导的自噬流阻滞在儿童T细胞急性淋巴细胞白血病化疗耐药逆转中的作用机制研究
- 批准号:82300182
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
PHF6突变通过相分离调控YTHDC2-m6A-SREBP2信号轴促进急性T淋巴细胞白血病发生发展的机制研究
- 批准号:82370165
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
- 批准号:82300697
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
KIF5B调控隧道纳米管介导的线粒体转运对FLT3-ITD阳性急性髓系白血病的作用机制
- 批准号:82370175
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
University of Washington Arboviral Research Network (UWARN)
华盛顿大学虫媒病毒研究网络 (UWARN)
- 批准号:
10687434 - 财政年份:2022
- 资助金额:
$ 16.76万 - 项目类别:
Characteristics of Transitions from Skilled Nursing Facility to Home Following Heart Failure Hospitalization
心力衰竭住院后从专业护理机构过渡到家庭的特点
- 批准号:
10711710 - 财政年份:2022
- 资助金额:
$ 16.76万 - 项目类别:
University of Washington Arboviral Research Network (UWARN)
华盛顿大学虫媒病毒研究网络 (UWARN)
- 批准号:
10493552 - 财政年份:2021
- 资助金额:
$ 16.76万 - 项目类别:
Optimizing Intensive Care Unit Staffing in the United States
优化美国重症监护病房的人员配置
- 批准号:
10611850 - 财政年份:2021
- 资助金额:
$ 16.76万 - 项目类别: